Philips logo

InnoSIGN logo

Capital Increase & Spin-out


Casdin Thuja logo Life Science Angels BOM logo
Sole Financial Adviser
;

InnoSIGN

Sole Financial Adviser

Kempen & Co acted as exclusive financial adviser in the transaction related to the spin-out and capital increase of InnoSIGN

Transaction highlights

  • InnoSIGN, a promising digital health scale-up, has successfully spun out of Philips and completed a Series A capital increase with a consortium of high quality US and European investors
  • Investors in the round include Casdin Capital, Life Sciences Angels, Thuja Capital and BOM. Philips owns a minority stake in the newly formed company
  • The proceeds of the round will be used to finance the spin-out from Philips and implement InnoSIGN’s ambitious growth plans to revolutionize precision medicine
  • Kempen & Co acted as exclusive financial adviser in this transaction
  • The transaction is a further testament to the joint effort of the Kempen & Co’s Life Sciences sector and Tech sector teams. It also underpins Kempen & Co’s strong position in M&A and fundraise advisory for growth companies
  • Since 2020, Kempen & Co advised on more than 95 transactions across 16 countries, representing a total deal value of €30 billion

About InnoSIGN

  • InnoSIGN commercialises its proprietary mRNA-based OncoSIGNal pathway activity profiling technology, revolutionizing precision medicine by obtaining more insight into the mechanisms of disease
  • The company leverages a combination of proprietary mRNA-based signalling pathway tests, a unique database with over 100 thousand pathway activity profiles, and advanced cloud-based analytics software
  • InnoSIGN is headquartered in the US and has R&D operations located at the High Tech Campus in Eindhoven, the Netherlands

Contact

Lennart den Blanken
Jan De Kerpel

Transactions